who invented glp 1 drugs Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions Discovery of GLP-1–Based Drugs for

Obesity is now recognized as a chronic, relapsing disease associated with increased risk of more than 200 conditions, including [3]: Type 2 diabetes Cardiovascular disease Obstructive sleep apnea Certain cancers Increased overall mortality Beyond individual patient risk, the system-level burden is substantial

This leads to the build-up of lipid intermediates such as long-chain acyl-CoAs, acylcarnitines, ceramides, diacylglycerols, and triacylglycerols within cardiomyocytes (52)

& Jin, L

Check-in on your weight, emotional and physical changes with an easy text or call

And thats an impressive reduction

Bydureon: Summary of product characteristics